Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by pcoopman
Last modified by standudu
Group name EquipePC
Item Type Journal Article
Title Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study
Creator Le Saux et al.
Author Olivia Le Saux
Author Audrey Lardy-Cleaud
Author Sophie Frank
Author Marc Debled
Author Paul H. Cottu
Author Barbara Pistilli
Author Laurence Vanlemmens
Author Marianne Leheurteur
Author Lilian Laborde
Author Lionel Uwer
Author Delphine Berchery
Author Veronique Lorgis
Author Jean-Marc Ferrero
Author Coralie Courtinard
Author Marie Ange Mouret-Reynier
Author Michel Velten
Author Mathias Breton
Author Damien Parent
Author Sylvie Chabaud
Author Mathieu Robain
Author Thomas Bachelot
Abstract BACKGROUND: For luminal metastatic breast cancer (MBC), endocrine therapy (ET) is the recommended initial treatment before chemotherapy. Our objective was to evaluate the efficacy of multiple ET lines in a real-life study. METHODS: The Breast Cancer Epidemiological Strategy and Medical Economics (ESME) project analysed data from all patients with systemic treatment for MBC initiated between 2008 and 2014 in one of the 18 French Comprehensive Cancer Centres. The primary end-point was the successive progression-free survival (PFS) evaluation. RESULTS: The ESME research programme included 9921 patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2) negative (HER2-) MBC. Before any chemotherapy, 4195 (43.4%), 1252 (29.8%) and 279 (6.6%) patients received one, two or three ET ± targeted therapy, respectively. The median PFS for first-, second- and third-line ET ± targeted therapy was 11.5 (95% confidence interval [CI], 10.8-12.1), 5.8 (95% CI, 5.3-6.1) and 5.5 (95% CI, 4.6-6.3) months, respectively. In a multivariate analysis, time from diagnosis to metastatic recurrence (P < 0.0001), presence of symptoms at metastatic relapse (P = 0.01), number of metastatic sites (P = 0.0003) and their localisation (P < 0.0001) were prognostic factors for PFS1. Duration of previous PFS was the only prognostic factor for subsequent PFS (10% threshold). Ten percent of the patients showed long-term response to ET, with a total treatment duration before chemotherapy ?43.6 months. CONCLUSIONS: Median PFS in our HR+/HER2- real-life cohort is similar to median first-line PFS reported in clinical trials, regardless of ET used as second- and third-line treatment. Despite the international consensus on early initiation of ET, the latter is not prescribed in most of the cases. Patients with a low tumour burden may achieve prolonged response on ET.
Publication European Journal of Cancer (Oxford, England: 1990)
Volume 118
Pages 131-141
Date Sep 2019
Journal Abbr Eur. J. Cancer
Language eng
DOI 10.1016/j.ejca.2019.06.014
ISSN 1879-0852
Short Title Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer
Library Catalog PubMed
Extra 00000 PMID: 31330488
Tags clinic, Exceptional response, Metastatic, Real-world data
Date Added 2019/09/13 - 10:04:09
Date Modified 2020/10/04 - 14:02:02
Notes and Attachments PubMed entry (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés